Let’s start up with the current stock price of GreenLight Biosciences Holdings (GRNA), which is $0.41 to be very precise. The Stock rose vividly during the last session to $0.427 after opening rate of $0.3337 while the lowest price it went was recorded $0.317 before closing at $0.34.Recently in News on March 9, 2023, GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day. GreenLight human health day image. You can read further details here
GreenLight Biosciences Holdings had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.1500 on 03/22/22, with the lowest value was $0.3170 for the same time period, recorded on 03/15/23.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
GreenLight Biosciences Holdings (GRNA) full year performance was -95.29%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, GreenLight Biosciences Holdings shares are logging -97.07% during the 52-week period from high price, and 30.31% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.32 and $14.15.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1237519 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the GreenLight Biosciences Holdings (GRNA) recorded performance in the market was -64.84%, having the revenues showcasing -63.92% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 69.75M, as it employees total of 312 workers.
GreenLight Biosciences Holdings (GRNA) in the eye of market guru’s
During the last month, 0 analysts gave the GreenLight Biosciences Holdings a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.1730, with a change in the price was noted -1.51. In a similar fashion, GreenLight Biosciences Holdings posted a movement of -78.39% for the period of last 100 days, recording 357,722 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for GRNA is recording 0.35 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.20.
GreenLight Biosciences Holdings (GRNA): Stocks Technical analysis and Trends
Raw Stochastic average of GreenLight Biosciences Holdings in the period of last 50 days is set at 10.49%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 18.49%. In the last 20 days, the company’s Stochastic %K was 9.05% and its Stochastic %D was recorded 4.90%.
If we look into the earlier routines of GreenLight Biosciences Holdings, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -64.84%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -78.50%, alongside a downfall of -95.29% for the period of the last 12 months. The shares increased approximately by -7.06% in the 7-day charts and went up by -47.54% in the period of the last 30 days. Common stock shares were lifted by -63.92% during last recorded quarter.
